Impact of lactoferrin supplementation on cotrimoxazole pharmacokinetics: A preliminary clinical investigation

Background and Purpose: Cotrimoxazole, a commonly prescribed antibiotic, has substantial resistance, especially in Indonesia, with its uropathogenic resistance reaching 67% in 2017. Although cotrimoxazole has been suggested to be co-administered with lactoferrin to enhance its antibacterial effectiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Dion Notario (Author), Angela Marietha Munzir (Author), Yulina Novella (Author), Linawati Hananta (Author)
Format: Book
Published: International Association of Physical Chemists (IAPC), 2024-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8be0eaa7c81d45a88aa31dbfeba5d6d0
042 |a dc 
100 1 0 |a Dion Notario  |e author 
700 1 0 |a Angela Marietha Munzir  |e author 
700 1 0 |a Yulina Novella  |e author 
700 1 0 |a Linawati Hananta  |e author 
245 0 0 |a Impact of lactoferrin supplementation on cotrimoxazole pharmacokinetics: A preliminary clinical investigation 
260 |b International Association of Physical Chemists (IAPC),   |c 2024-06-01T00:00:00Z. 
500 |a 10.5599/admet.2358 
500 |a 1848-7718 
520 |a Background and Purpose: Cotrimoxazole, a commonly prescribed antibiotic, has substantial resistance, especially in Indonesia, with its uropathogenic resistance reaching 67% in 2017. Although cotrimoxazole has been suggested to be co-administered with lactoferrin to enhance its antibacterial effectiveness and this practice has been widely adopted since the Covid-19 pandemic, the impact of lactoferrin on the pharmacokinetics of cotrimoxazole remains relatively unknown. This study aims to conduct a preliminary clinical investigation into the impact of lactoferrin supplementation on the pharmacokinetics of cotrimoxazole, focusing on the elimination rate and excretion of unchanged drug in urine. Experimental Approach: This study employed a blinded, cross-over, single-dose pharmacokinetics investigation, which included five healthy volunteers as participants. In the initial period, the first group received cotrimoxazole (80 mg trimethoprim and 400 mg sulfamethoxazole) along with a lactoferrin-containing supplement, while the second group only received cotrimoxazole. Subsequently, after a washout period, the conditions were reversed. Urine sampling was conducted at intervals from 0 to 24 hours post-medication, and drug levels in the urine were determined using high-performance liquid chromatography. Key Results: The population-based pharmacokinetic analysis revealed that the optimal model was the one-compartment model with first-order elimination and proportional residual error. Conclusion: The findings show that the administration of lactoferrin-containing supplements did not significantly influence the covariate model and, therefore, did not alter the pharmacokinetics parameter of cotrimoxazole in urine with a single administration, implying that lactoferrin did not cause drug interaction problems when given simultaneously. 
546 |a EN 
690 |a population pharmacokinetics 
690 |a urinary excretion 
690 |a one-compartment 
690 |a drug interaction 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n ADMET and DMPK (2024) 
787 0 |n https://pub.iapchem.org/ojs/index.php/admet/article/view/2358 
787 0 |n https://doaj.org/toc/1848-7718 
856 4 1 |u https://doaj.org/article/8be0eaa7c81d45a88aa31dbfeba5d6d0  |z Connect to this object online.